Brendan P. Eckelman
2021
In 2021, Brendan P. Eckelman earned a total compensation of $1.7M as Chief Scientific Officer at Inhibrx, a 182% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $180,000 |
|---|---|
| Option Awards | $1,017,322 |
| Salary | $450,000 |
| Other | $14,500 |
| Total | $1,661,822 |
Eckelman received $1M in option awards, accounting for 61% of the total pay in 2021.
Eckelman also received $180K in non-equity incentive plan, $450K in salary and $14.5K in other compensation.
Rankings
In 2021, Brendan P. Eckelman's compensation ranked 6,805th out of 12,415 executives tracked by ExecPay. In other words, Eckelman earned more than 45.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,805 out of 12,415 | 45th |
Division Manufacturing | 2,958 out of 5,508 | 46th |
Major group Chemicals And Allied Products | 1,309 out of 2,378 | 45th |
Industry group Drugs | 1,167 out of 2,099 | 44th |
Industry Biological Products, Except Diagnostic Substances | 276 out of 449 | 39th |
Source: SEC filing on April 13, 2022.
Eckelman's colleagues
We found three more compensation records of executives who worked with Brendan P. Eckelman at Inhibrx in 2021.